This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-consensus: Archive
Wall Street Analysts See a 31.58% Upside in Mama's Creations, Inc. (MAMA): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Mama's Creations, Inc. (MAMA) points to a 31.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MAMAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
HCMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Can Marcus (MCS) Climb 44.69% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Marcus (MCS) points to a 44.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
MCSNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in PAR Technology (PAR)? Wall Street Analysts Think 33.49%
by Zacks Equity Research
The mean of analysts' price targets for PAR Technology (PAR) points to a 33.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
PARNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Oxford Industries (OXM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Oxford Industries (OXM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OXMPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate J.Jill (JILL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
J.Jill (JILL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JILLPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does HNI (HNI) Have the Potential to Rally 47.06% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 47.1% upside potential for HNI (HNI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
HNIPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Knot Offshore (KNOP)? Wall Street Analysts Think 106.1%
by Zacks Equity Research
The consensus price target hints at a 106.1% upside potential for Knot Offshore (KNOP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
KNOPNo Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
How Much Upside is Left in Intellia Therapeutics (NTLA)? Wall Street Analysts Think 398.31%
by Zacks Equity Research
The consensus price target hints at a 398.3% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
NTLAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Energy Transfer LP (ET) Have the Potential to Rally 28.1% as Wall Street Analysts Expect?
by Zacks Equity Research
The consensus price target hints at a 28.1% upside potential for Energy Transfer LP (ET). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ETNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think FTAI Aviation (FTAI) Could Surge 38.63%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 38.6% upside potential for FTAI Aviation (FTAI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
FTAINegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Agenus (AGEN) points to a 26.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AGENPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
AMRXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 28.33% Upside in Rambus (RMBS): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 28.3% upside potential for Rambus (RMBS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
RMBSPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 76.7% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
ZYMENegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at a 138.8% upside potential for Centessa Pharmaceuticals (CNTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
CNTAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Smucker (SJM) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Smucker (SJM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SJMPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Dave & Buster's (PLAY) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Dave & Buster's (PLAY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLAYPositive Net Change CBRLPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Does Arcosa (ACA) Have the Potential to Rally 26.49% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Arcosa (ACA) points to a 26.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ACAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Immatics (IMTX) Have the Potential to Rally 174.54% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Immatics (IMTX) points to a 174.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
IMTXPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ARCTNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Predict a 44.7% Upside in Contango ORE, Inc. (CTGO): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Contango ORE, Inc. (CTGO) points to a 44.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CTGONegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts Think Aardvark Therapeutics, Inc. (AARD) Could Surge 180.77%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Aardvark Therapeutics, Inc. (AARD) points to an 180.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
AARDPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Skillsoft Corp. (SKIL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Skillsoft (SKIL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SKILPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts Believe Ooma (OOMA) Could Rally 34.07%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 34.1% upside potential for Ooma (OOMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
OOMAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate